Role of low molecular weight heparin (LMWH) in central venous catheter antithrombotic prophylaxis
2007
9010 Background: To assess the role of LMWH in antithrombotic prophylaxis in cancer patients with a central venous catheter. Methods: A systematic review of literature in the MEDLINE and EMBASE data bases from 1966 to October 2006, using “anticoagulants/*administration & dosage” [MeSH term], “cancer patient” [MeSH term], “catheterization, central venous/*adverse effect” [MeSH term], “catheters, indwelling/adverse effects” “central venous catheter” [MeSH term], “dalteparin/*administration and dosage” [MeSH term], “enoxaparin/*administration and dosage” [MeSH term], “low molecular weight heparin/*administration and dosage” [MeSH term], “nadroparin/*administration and dosage” [MeSH term], “neoplasm/drug therapy” [MeSH term], “reviparin/*administration and dosage” [MeSH term], “venous thrombosis/*etiology/*prevention & control/radiography” [MeSH term], a search was performed independently by two authors (DT and ES). All the randomized phase III trials comparing LMWH and placebo were considered eligible and in...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI